<http://webisa.webdatacommons.org/390237026>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<regeneron.com> .
<http://webisa.webdatacommons.org/prov/256758683>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/390237026> .
<http://webisa.webdatacommons.org/390237026>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/390237026>	<http://www.w3.org/ns/prov#value>	"f neovascular age-related macular degeneration (wet AMD) in Japan, Europe, Australia, and other regions, and we expect to see substantial sales growth through 2013 and beyond as pricing approvals are received." .